Compare the GLP-1 weight loss drugs
7 of the 8 GLP-1 products carry a brand licence and they are not interchangeable. 3 are licensed for weight management and 4 for type 2 diabetes, two of those sharing a molecule with a weight drug under another brand. A payer can cover one brand and exclude its twin.
By the Covered Weight editorial team · Updated Aug 8, 2026. Research and sourcing by Evan Reid.
What each product is licensed to treat
Sort by what a product treats to see the split that decides most coverage questions: a licence for weight management is a different document from a licence for type 2 diabetes, and payers read them separately.
| Drug | Molecule | Approved for |
|---|---|---|
| Mounjaro®Eli Lilly and Company | tirzepatide | type 2 diabetes5 |
| Ozempic®Novo Nordisk A/S | semaglutide | type 2 diabetes, cardiovascular risk2 |
| Rybelsus®Novo Nordisk A/S | semaglutide | type 2 diabetes3 |
| Saxenda®Novo Nordisk A/S | liraglutideauthorized generic sold | weight67 |
| Victoza®Novo Nordisk A/S | liraglutideauthorized generic sold | type 2 diabetes, cardiovascular risk89 |
| Wegovy®Novo Nordisk A/S | semaglutide | weight, cardiovascular risk1 |
| Zepbound®Eli Lilly and Company | tirzepatide | weight, sleep apnea4 |
| Mounjaro®Eli Lilly and Company | tirzepatide | type 2 diabetes5 |
| Rybelsus®Novo Nordisk A/S | semaglutide | type 2 diabetes3 |
| Ozempic®Novo Nordisk A/S | semaglutide | type 2 diabetes, cardiovascular risk2 |
| Victoza®Novo Nordisk A/S | liraglutideauthorized generic sold | type 2 diabetes, cardiovascular risk89 |
| Saxenda®Novo Nordisk A/S | liraglutideauthorized generic sold | weight67 |
| Wegovy®Novo Nordisk A/S | semaglutide | weight, cardiovascular risk1 |
| Zepbound®Eli Lilly and Company | tirzepatide | weight, sleep apnea4 |
Which programs paid for the most, per person enrolled
Missouri paid for the most GLP-1 prescriptions per enrollee of the 51 jurisdictions with both figures on file, at 92.2 per thousand people enrolled in 2026Q1. That is a ranking of programs rather than of populations, which a raw prescription count cannot give: the largest programs top every absolute list simply by being largest.
Each rate is a range because the federal file withholds any count too small to publish, so a jurisdiction outranks another only where its lower bound clears the other's upper bound. On that test Missouri is genuinely above 50 of the other 50; the rest overlap it and this data cannot separate them.
Show all 51 jurisdictions by prescriptions per thousand enrollees
| Jurisdiction | Per thousand enrollees | Quarter | Enrollees averaged |
|---|---|---|---|
| Missouri | 92.2 | 2026Q1 | 1,130,743 |
| Massachusetts | 73.8 to 73.9 | 2026Q1 | 1,388,059 |
| Wisconsin | 72.5 to 72.6 | 2026Q1 | 1,027,783 |
| Michigan | 60.0 to 60.1 | 2026Q1 | 2,050,294 |
| Tennessee | 50.9 to 51.0 | 2026Q1 | 1,224,155 |
| West Virginia | 47.4 to 47.6 | 2026Q1 | 448,064 |
| Rhode Island | 46.0 to 46.8 | 2026Q1 | 257,860 |
| Delaware | 45.1 to 46.2 | 2026Q1 | 224,604 |
| North Carolina | 44.1 to 44.2 | 2026Q1 | 2,520,312 |
| Kentucky | 43.7 to 44.0 | 2026Q1 | 1,182,642 |
| Minnesota | 42.8 to 42.9 | 2026Q1 | 1,146,749 |
| California | 42.3 | 2026Q1 | 11,178,145 |
| Idaho | 37.9 to 38.2 | 2026Q1 | 294,691 |
| Connecticut | 37.6 to 37.7 | 2026Q1 | 879,065 |
| New York | 33.9 | 2026Q1 | 5,812,533 |
| Louisiana | 32.1 to 32.2 | 2026Q1 | 1,245,380 |
| Maryland | 31.8 to 32.0 | 2026Q1 | 1,203,259 |
| South Dakota | 30.4 to 31.5 | 2026Q1 | 124,684 |
| Iowa | 30.1 to 30.5 | 2026Q1 | 590,886 |
| District of Columbia | 28.9 to 30.2 | 2026Q1 | 224,478 |
| Nevada | 26.8 to 27.1 | 2026Q1 | 679,835 |
| Indiana | 26.6 to 26.7 | 2026Q1 | 1,337,300 |
| Nebraska | 26.2 to 26.6 | 2026Q1 | 300,564 |
| Alaska | 25.5 to 26.1 | 2026Q1 | 198,822 |
| Kansas | 25.4 to 25.7 | 2026Q1 | 328,921 |
| Colorado | 25.4 to 25.6 | 2026Q1 | 1,054,612 |
| Montana | 25.2 to 25.7 | 2026Q1 | 190,341 |
| Alabama | 24.7 to 24.8 | 2026Q1 | 747,304 |
| New Mexico | 24.3 to 24.7 | 2026Q1 | 640,512 |
| Mississippi | 24.0 to 24.5 | 2026Q1 | 508,725 |
| Vermont | 23.4 to 23.7 | 2026Q1 | 144,427 |
| North Dakota | 23.2 to 24.2 | 2026Q1 | 101,142 |
| New Hampshire | 21.2 to 22.1 | 2026Q1 | 155,465 |
| Wyoming | 20.1 to 21.4 | 2026Q1 | 55,316 |
| Pennsylvania | 19.5 to 19.6 | 2026Q1 | 2,734,998 |
| Utah | 19.3 to 20.3 | 2026Q1 | 296,751 |
| Virginia | 18.0 to 18.1 | 2026Q1 | 1,485,108 |
| Maine | 17.9 to 18.1 | 2026Q1 | 315,765 |
| Washington | 17.3 to 17.4 | 2026Q1 | 1,726,267 |
| Hawaii | 16.3 to 16.4 | 2026Q1 | 362,000 |
| New Jersey | 16.0 to 16.2 | 2026Q1 | 1,510,027 |
| South Carolina | 15.9 to 16.2 | 2026Q1 | 869,608 |
| Texas | 12.3 | 2026Q1 | 3,698,515 |
| Oregon | 11.4 to 11.7 | 2026Q1 | 1,111,552 |
| Oklahoma | 10.5 to 10.7 | 2026Q1 | 889,811 |
| Georgia | 8.9 to 9.0 | 2026Q1 | 1,687,108 |
| Ohio | 7.7 to 7.8 | 2026Q1 | 2,441,828 |
| Illinois | 7.6 | 2026Q1 | 2,686,717 |
| Florida | 7.5 | 2026Q1 | 3,414,095 |
| Arkansas | 6.1 to 6.4 | 2026Q1 | 717,884 |
| Arizona | 2.2 | 2026Q1 | 1,535,845 |
What a state Medicaid program actually paid for
The table above is the licence. What a program PAID for is published per jurisdiction in the federal file, so it lives on each of the 51 jurisdiction pages.
With the coverage rule read and quoted
Payment history, plus the rule deciding the next request.
Federal payment record only
What the program paid, cited to the federal file. Rule not read yet.
- Alabama
- Alaska
- Arizona
- Arkansas
- Colorado
- Connecticut
- Delaware
- District of Columbia
- Florida
- Georgia
- Hawaii
- Idaho
- Illinois
- Indiana
- Iowa
- Kansas
- Kentucky
- Louisiana
- Maine
- Maryland
- Massachusetts
- Michigan
- Minnesota
- Mississippi
- Missouri
- Montana
- Nebraska
- Nevada
- New Hampshire
- New Jersey
- New Mexico
- North Carolina
- North Dakota
- Oklahoma
- Oregon
- Pennsylvania
- Rhode Island
- South Carolina
- South Dakota
- Tennessee
- Utah
- Vermont
- Virginia
- Washington
- West Virginia
- Wisconsin
- Wyoming
Want to pivot this across jurisdictions and quarters? The GLP-1 coverage explorer loads the same figures with a five-quarter trend for each product, and every view is a shareable link. It needs JavaScript; this page never will.
Documents this page reads
9 documents, cited by number above. Each opens to its section, its effective date, and the quote the fact came from.
DailyMed, Wegovy® (semaglutide) label, Indications and Usage
WEGOVY (semaglutide) injection, for subcutaneous use, INDICATIONS AND USAGE
National Library of Medicine · FDA label · Read Aug 8, 2026
to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight.
Read Aug 8, 2026
DailyMed, Ozempic® (semaglutide) label, Indications and Usage
OZEMPIC (semaglutide) injection, for subcutaneous use, INDICATIONS AND USAGE
National Library of Medicine · FDA label · Read Aug 8, 2026
glycemic control in adults with type 2 diabetes mellitus. (1) • to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular
Read Aug 8, 2026
DailyMed, Rybelsus® (semaglutide) label, Indications and Usage
RYBELSUS (semaglutide) tablets, for oral use, INDICATIONS AND USAGE
National Library of Medicine · FDA label · Read Aug 8, 2026
RYBELSUS and OZEMPIC tablets are glucagon-like peptide-1 (GLP-1) receptor agonists indicated: • as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Read Aug 8, 2026
DailyMed, Zepbound® (tirzepatide) label, Indications and Usage
ZEPBOUND (tirzepatide) injection, for subcutaneous use, INDICATIONS AND USAGE
National Library of Medicine · FDA label · Read Aug 8, 2026
adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. (1) to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity.
Read Aug 8, 2026
DailyMed, Mounjaro® (tirzepatide) label, Indications and Usage
MOUNJARO (tirzepatide) injection, for subcutaneous use, INDICATIONS AND USAGE
National Library of Medicine · FDA label · Read Sep 7, 2026
as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.
Read from the Indications and Usage summary on the DailyMed label page. The page is HTML, so the quote is the text layer with runs of whitespace collapsed; the label prints no other transformation. RE-READ 2026-09-07 after verify-quotes reported the previous quote absent. The document was republished: an 08/2026 revision adds a second indication to section 1 (reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes at high risk), which turned the single-indication sentence into a colon and a list. The stored quote had opened with the shared lead-in word "indicated", which now sits before the colon rather than before this clause, so the quote stopped being verbatim while the fact it backs did not change. The quote now starts at the clause. The added indication is still scoped to type 2 diabetes and does not make this product a weight management drug, so drugs.tirzepatide_mounjaro.indications is unchanged and its sibling Zepbound remains the weight management brand. Read Sep 7, 2026
DailyMed, Saxenda® (liraglutide) label, Indications and Usage
SAXENDA (liraglutide) injection, for subcutaneous use, INDICATIONS AND USAGE
National Library of Medicine · FDA label · Read Aug 8, 2026
excess body weight and maintain weight reduction long term in: • Adults and pediatric patients aged 12 years and older with body weight greater than 60 kg and obesity. (1) • Adults with overweight
Read Aug 8, 2026
DailyMed, Liraglutide injection, solution (Teva Pharmaceuticals, Inc.), Indications and Usage
Liraglutide injection, for subcutaneous use, INDICATIONS AND USAGE
National Library of Medicine · FDA label · Read Aug 8, 2026
Liraglutide injection is a glucagon like peptide-1 (GLP-1) receptor agonist indicated in combination with a reduced-calorie diet and incr
Read Aug 8, 2026
DailyMed, Victoza® (liraglutide) label, Indications and Usage
VICTOZA (liraglutide) injection, for subcutaneous use, INDICATIONS AND USAGE
National Library of Medicine · FDA label · Read Aug 8, 2026
to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. (1) • to reduce the risk of major adverse cardiovascular events in adults
Read Aug 8, 2026
DailyMed, Liraglutide injection (Hikma Pharmaceuticals USA Inc.), Indications and Usage
Liraglutide injection, for subcutaneous use, INDICATIONS AND USAGE
National Library of Medicine · FDA label · Read Aug 8, 2026
Liraglutide injection is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated: as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years
Read Aug 8, 2026
How the quoted row is presented, for 8 of these documents
Read from the Indications and Usage summary on the DailyMed label page. The page is HTML, so the quote is the text layer with runs of whitespace collapsed; the label prints no other transformation.
Common questions
Are Ozempic® and Wegovy® the same drug?
They are the same molecule, semaglutide, sold under two brand names with two different labels. Wegovy® is licensed for weight management and Ozempic® for type 2 diabetes. A payer can cover one and exclude the other on the same day, which is why this table lists them as separate rows.
Why does one row say a figure is withheld rather than zero?
The federal payment file suppresses a count too small to publish. A withheld cell means prescriptions were paid for and the number is not disclosed, so treating it as zero would be wrong. Where a jurisdiction withheld part of a total, the figure shown is a floor and the page says so.
Does this table tell me whether my plan covers a drug?
No. It shows what each product is licensed for and, on a jurisdiction page, what that state Medicaid program actually paid for. A payment record is not a coverage rule, and no state rule reaches a self-funded employer plan at all. Check which document governs your plan first.